Abacus FCF Advisors’s NovoCure NVCR Stock Holding History

Abacus FCF Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,708	Closed	-$721K	–	165
2022 Q1	$721K	Buy	+8,708	New	+$641K	0.24%	159

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Abacus FCF Advisors's NVCR Position: Q2 2022 in Review

Abacus FCF Advisors sold out of NovoCure (NVCR) in Q2 2022, closing a stake of 8,708 shares — an estimated $721K sold.

Abacus FCF Advisors first reported a position in NVCR in Q1 2022 and held it in 1 quarter. The position peaked at $721K in Q1 2022. 316 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

Abacus FCF Advisors reported no remaining NovoCure position as of Q2 2022 after selling out during the quarter.
Abacus FCF Advisors sold 8,708 NovoCure shares in Q2 2022, an estimated $721K.
Abacus FCF Advisors first reported a position in NovoCure in Q1 2022 and held it in 1 quarter.
Abacus FCF Advisors's NovoCure position peaked at $721K in Q1 2022.
316 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on Abacus FCF Advisors's 13F filing for Q2 2022, filed 20 Jul 2022.